EDWIN CLARK, Ph.D.
ExecutiveDirector, Oncology Basic Research
Site Lead, Boston

Dr. Clark arrived in October 2008 at MRL-Boston as Executive Director, Oncology Basic Research Site Lead, Boston.  His team is focused on ensuring that Merck pipeline compounds have the appropriate basal markers for identification of cancer subpopulations, intermediate markers needed to identify early therapeutic response, and scientific support to strategically guide therapeutic combinations.  From 2003 through 2008 Dr. Clark led a team of scientists as Group Director, Clinical Biomarkers in the Department of Discovery Medicine at Bristol-Myers Squibb.  His team focused on the identification and use of biomarkers in clinical development.  In this capacity, he directed teams focused on pharmacodynamic and predictive biomarkers in preclinical, early-, and late-clinical programs.  In addition, Dr. Clark co-chaired an exploratory development team responsible for the early development of a number of cancer therapies at Bristol-Myers Squibb including SPRYCEL™ (dasatinib).

Prior to joining Bristol-Myers Squibb, Dr. Clark was with the Department of Molecular Medicine/Oncology at Millennium Pharmaceuticals, Inc. and was responsible for a genomics collaboration with MD Anderson Cancer Center, Mayo Clinic, and Bristol-Myers Squibb.  Dr. Clark performed post-doctoral research in the laboratory of Dr. Richard Hynes at the Center for Cancer Research at the Massachusetts Institute of Technology (MIT) where, in collaboration with Drs. Todd Golub and Eric Lander at the MIT/Whitehead Genome Center, he completed research on the role of genes regulating cancer metastasis.  Dr. Clark earned his Ph.D. in Cell Biology in 1994 from the University of Pennsylvania School of Medicine.  His thesis work, performed in the laboratory of Dr. Joan Brugge, focused on tyrosine kinase signaling from adhesion receptors.

Key Publications 2004 - Present
Wang X, Reeves K, Luo R, Wu S, Xu L, Ayers M, Lee F, Clark E, Huang F (2007) Identification of Predictive and Surrogate Molecular Markers for Dasatinib in Prostate Cancer: Rationale for Patient Selection and Efficacy Monitoring. Genome Biol 8: R255.1-11.

Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wong T, Huang X, Takimoto CH, Godwin AG, Tan BR, Krishnamurthi SS, Burris III HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ  (2007) Expression of epiregulin and amphiregulin and K-RAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 25: 3230-3237.

Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong T, Lee F, Shaw P, Clark E (2007) Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection.  Cancer Res 67: 2227-2238.

Serrels A, Iain R.J. Macpherson, Evans TRJ, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, and Brunton VG (2006) Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.  Mol Cancer Ther 5: 3014-3022.

Ross JS, Linnette GP, Stec J, Clark E, Symmans F, Hortobagyi GN,Pusztai L. The molecular pathology of breast cancer. In Leonard D. Molecular Pathology in Clinical Practice (New York; Springer-Verlag, 2006) pp 263-272.

Wanger P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L (2005)  Microtubule Associated Protein (MAP) Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo. Cell Cycle.  4:1149-1152.

Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli DR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross J, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI (2005)  Gene Expression Profiles Predict Early Relapse in Ovarian Cancer After Platinum-Paclitaxel Chemotherapy. Clin Cancer Res. 11:2149-2155.

Ayers M., Symmans WF, Stec J, Damokosh A, Clark E, Hess K, Lecocke M, Metivier J, Bolt A, Brown J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, and Pusztai L (2004)  Identification of Genomic Markers That Predict Complete Pathological Response to Neoadjuvant Paclitaxel/FAC Chemotherapy in Breast Cancer. J Clin Oncol. 22:2284-2293.

Ross JS, Linette GP, Stec J, Clark E, Ayers M, Leschly N, Symmans WF, Hortobagyi GN, Pusztai L. (2004) Breast Cancer Biomarkers and Molecular Medicine: part II.
Expert Rev Mol Diagn. 4:169-88.